

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*Unless otherwise defined herein, terms used in this announcement shall have the same meanings as those defined in the prospectus dated September 5, 2017 (the “**Prospectus**”) issued by Sisram Medical Ltd (the “**Company**”).*

This announcement is made pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong).

This announcement is for information purpose only and does not constitute an invitation or offer to acquire, purchase or subscribe for Shares or any securities. Potential investors should read the Prospectus for detailed information about the Global Offering illustrated below before deciding whether or not to invest in the Shares.

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer to sell or solicitation to purchase or subscribe for securities in the United States or in any other jurisdictions. The Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended from time to time (the “**U.S. Securities Act**”) or any state securities laws of the United States and may be offered and sold (a) in the United States only to persons who are both “*Qualified Institutional Buyers*” and “*Qualified Purchasers*” in reliance on Rule 144A or another exemption from, or in a transaction not subject to, registration under the U.S. Securities Act and (b) outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act. The Company has not intended and does not intend to make any public offer of securities in the United States. Any public offering of securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company and that will contain detailed information about the Company and management, as well as financial statements. No registration has been or will be made under the United States Investment Company Act of 1940.*

Sisram Medical Ltd

(Incorporated in Israel with limited liability)

(Stock Code: 1696)

PARTIAL EXERCISE OF THE OVER-ALLOTMENT OPTION, STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

PARTIAL EXERCISE OF THE OVER-ALLOTMENT OPTION

The Company announces that the Over-allotment Option was partially exercised by the Joint Global Coordinators (on behalf of the International Underwriters) on October 8, 2017 in respect of an aggregate of 2,155,600 Shares (the

“**Over-allotment Shares**”), representing approximately 1.96% of the total number of the Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option, to facilitate the return to Ample Up Limited of part of the borrowed Shares which were used to cover over-allocations in the International Offering.

The Over-allotment Shares will be issued and allotted by the Company at HK\$8.88 per Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%), being the Offer Price per Offer Share under the Global Offering.

STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

The Company announces that the stabilization period in connection with the Global Offering ended on October 8, 2017, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering.

The stabilizing actions undertaken by China International Capital Corporation Hong Kong Securities Limited, its affiliates or any person acting for it, being the Stabilizing Manager, during the stabilization period involved:

- (i) over-allocations of an aggregate of 16,500,000 Shares in the International Offering, representing 15% of the Offer Shares initially available under the Global Offering before the exercise of the Over-allotment Option;
- (ii) borrowing of an aggregate of 16,500,000 Shares by China International Capital Corporation Hong Kong Securities Limited from Ample Up Limited to cover over-allocations in the International Offering;
- (iii) successive purchases of an aggregate of 14,344,400 Shares in the price range of HK\$8.09 to HK\$8.88 per Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%) on the market during the stabilisation period. The last purchase made by the Stabilising Manager on the market during the stabilisation period was on October 6, 2017 at the price of HK\$8.88 per Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%);
- (iv) the partial exercise of Over-allotment Option by the Joint Global Coordinators (on behalf of the International Underwriters) on October 8, 2017 in respect of an aggregate of 2,155,600 Shares, representing approximately 1.96% of the total number of the Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option, to facilitate the return to Ample Up Limited of part of the borrowed Shares which were used to cover over-allocations in the International Offering; and
- (v) the portion of the Over-allotment Option which has not been exercised by the Joint Global Coordinators, on behalf of the International Underwriters, lapsed on October 8, 2017.

PARTIAL EXERCISE OF THE OVER-ALLOTMENT OPTION

The Company announces that the Over-allotment Option was partially exercised by the Joint Global Coordinators (on behalf of the International Underwriters) on October 8, 2017 in respect of an aggregate of 2,155,600 Shares, representing approximately 1.96% of the total number of the Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option, to facilitate the return to Ample Up Limited of part of the borrowed Shares which were used to cover over-allocations in the International Offering.

The Over-allotment Shares will be issued and allotted by the Company at HK\$8.88 per Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%), being the Offer Price per Offer Share under the Global Offering.

Approval of Listing

Approval for the listing of and permission to deal in the Over-allotment Shares has already been granted by the Listing Committee of the Stock Exchange. Listing of and dealings in the Over-allotment Shares are expected to commence on the Main Board of the Stock Exchange at 9:00 a.m. on October 11, 2017.

Share Capital upon the Partial Exercise of Over-allotment Option

The shareholding structure of the Company immediately before and immediately after the completion of the partial exercise of the Over-allotment Option is as follows:

Shareholders	Immediately before the allotment and issue of the Over-allotment Shares		Immediately after the allotment and issue of the Over-allotment Shares	
	<i>Number of Shares</i>	<i>Approximate % of the Company's issued share capital</i>	<i>Number of Shares</i>	<i>Approximate % of the Company's issued share capital</i>
CML	127,318,640	28.94%	127,318,640	28.79%
Ample Up	105,705,360	24.02%	105,705,360	23.91%
Magnificent View	96,976,000	22.04%	96,976,000	21.93%
Public Shareholders	<u>110,000,000</u>	<u>25.00%</u>	<u>112,155,600</u>	<u>25.37%</u>
Total	<u>440,000,000</u>	<u>100.00%</u>	<u>442,155,600</u>	<u>100.00%</u>

Use of Proceeds

The additional net proceeds of approximately HK\$18.3 million to be received by the Company from the allotment and issue of the Over-allotment Shares after deducting the underwriting commissions and other estimated expenses in connection with the partial exercise of the Overallotment Option, will be used by the Company for the purposes as set out in the section headed “Future Plans and Use of Proceeds — Use of Proceeds” in the Prospectus.

STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

The Company announces, pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong), that the stabilization period in connection with the Global Offering ended on October 8, 2017.

The stabilizing actions undertaken by China International Capital Corporation Hong Kong Securities Limited, its affiliates or any person acting for it, being the Stabilizing Manager, during the stabilization period involved:

- (i) over-allocations of an aggregate of 16,500,000 Shares in the International Offering, representing 15% of the Offer Shares initially available under the Global Offering before the exercise of the Over-allotment Option;
- (ii) borrowing of an aggregate of 16,500,000 Shares by China International Capital Corporation Hong Kong Securities Limited from Ample Up Limited to cover over-allocations in the International Offering;
- (iii) successive purchases of an aggregate of 14,344,400 Shares in the price range of HK\$8.09 to HK\$8.88 per Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%) on the market during the stabilisation period. The last purchase made by the Stabilising Manager on the market during the stabilisation period was on October 6, 2017 at the price of HK\$8.88 per Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%);
- (iv) the partial exercise of Over-allotment Option by the Joint Global Coordinators (on behalf of the International Underwriters) on October 8, 2017 in respect of an aggregate of 2,155,600 Shares, representing approximately 1.96% of the total number of the Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option, to facilitate the return to Ample Up Limited of part of the borrowed Shares which were used to cover over-allocations in the International Offering; and

(v) the portion of the Over-allotment Option which has not been exercised by the Joint Global Coordinators, on behalf of the International Underwriters, lapsed on October 8, 2017.

PUBLIC FLOAT

Immediately after the allotment and issue of the Over-allotment Shares, the Company will continue to comply with the public float requirements under Rule 8.08(1)(a) of the Listing Rules.

By order of the Board of Directors
Sisram Medical Ltd
LIU Yi
Chairman

Hong Kong, October 8, 2017

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Yi LIU and Mr. Lior Moshe DAYAN as Executive Directors; Mr. Yifang WU, Mr. Chun LI, Mr. Yao WANG, and Ms. Yu HU as Non-Executive Directors; Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU as Independent Non-executive Directors.